$438 Million is the total value of Opaleye Management Inc.'s 51 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 39.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OCUL | Sell | OCULAR THERAPEUTIX INC | $36,303,300 | -40.0% | 5,307,500 | -20.2% | 8.30% | -37.1% |
| EWTX | Sell | EDGEWISE THERAPEUTICS INC | $10,445,800 | -13.9% | 580,000 | -12.8% | 2.39% | -9.7% |
| CPRX | Sell | CATALYST PHARMACEUTICALS INC | $9,913,600 | -38.1% | 640,000 | -36.3% | 2.26% | -35.1% |
| Sell | JASPER THERAPEUTICS INC | $8,898,400 | -30.4% | 392,000 | -10.0% | 2.03% | -27.1% | |
| ETON | Sell | ETON PHARMACEUTICALS INC | $7,879,550 | -14.1% | 2,395,000 | -2.1% | 1.80% | -10.0% |
| APLT | Sell | APPLIED THERAPEUTICS INC' | $7,845,600 | -34.8% | 1,680,000 | -5.1% | 1.79% | -31.6% |
| Sell | NEWAMSTERDAM PHARMA COMPANYordinary shares | $6,051,150 | -18.9% | 315,000 | -0.1% | 1.38% | -14.9% | |
| TARA | Sell | PROTARA THERAPEUTICS INC | $5,299,803 | -50.9% | 2,304,262 | -14.4% | 1.21% | -48.5% |
| NTLA | Sell | INTELLIA THERAPEUTICS INC | $4,878,840 | -30.5% | 218,000 | -14.5% | 1.12% | -27.1% |
| LQDA | Sell | LIQUIDIA CORPORATION | $3,900,000 | -33.1% | 325,000 | -17.7% | 0.89% | -29.8% |
| PTGX | Sell | PROTAGONIST THERAPEUTICS INC | $3,638,250 | +11.6% | 105,000 | -6.8% | 0.83% | +16.9% |
| SVRA | Sell | SAVARA INC | $2,881,289 | -32.3% | 714,960 | -16.4% | 0.66% | -29.1% |
| Sell | VENTYX BIOSCIENCES INC | $2,748,900 | -61.1% | 1,190,000 | -7.4% | 0.63% | -59.2% | |
| LYEL | Sell | LYELL IMMUNOPHARMA INC | $2,421,500 | -67.6% | 1,670,000 | -50.2% | 0.55% | -66.1% |
| RLMD | Sell | RELMADA THERAPEUTICS INC | $1,800,000 | -49.0% | 600,000 | -20.9% | 0.41% | -46.6% |
| Sell | IBIO INC | $791,250 | -71.3% | 375,000 | -44.9% | 0.18% | -69.9% | |
| ALGS | Sell | ALIGOS THERAPEUTICS INC | $441,000 | -72.4% | 1,260,000 | -22.7% | 0.10% | -71.0% |
| RPTX | Exit | REPARE THERAPEUTICS iNC | $0 | – | -67,561 | -100.0% | -0.07% | – |
| GKOS | Exit | GLAUKOS CORP | $0 | – | -8,576 | -100.0% | -0.18% | – |
| MOR | Exit | MORPHOSYS AGsponsored ads | $0 | – | -65,000 | -100.0% | -0.26% | – |
| LRMR | Exit | LARIMAR THERAPEUTICS INC | $0 | – | -174,413 | -100.0% | -0.29% | – |
| PGEN | Exit | PRECIGEN INC | $0 | – | -947,500 | -100.0% | -0.30% | – |
| Exit | CONTEXT THERAPEUTICS INC | $0 | – | -1,108,357 | -100.0% | -0.33% | – | |
| ZNTL | Exit | ZENTALIS PHARMACEUTICALS INC | $0 | – | -200,000 | -100.0% | -0.69% | – |
| RVNC | Exit | REVANCE THERAPEUTICS INC | $0 | – | -785,000 | -100.0% | -0.84% | – |
| Exit | NYXOAH S A | $0 | – | -320,000 | -100.0% | -0.94% | – | |
| CMPX | Exit | COMPASS THERAPEUTICS INC | $0 | – | -3,170,000 | -100.0% | -1.37% | – |
| CRNX | Exit | CRINETICS PHARMACEUTICALS INC | $0 | – | -210,000 | -100.0% | -2.14% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 42 | Q2 2024 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 30 | Q2 2024 | 3.6% |
| OCULAR THERAPEUTIX INC | 27 | Q2 2024 | 17.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| ETON PHARMACEUTICALS INC | 23 | Q2 2024 | 5.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| TG THERAPEUTICS INC | 20 | Q2 2024 | 10.1% |
| CRINETICS PHARMACEUTICALS INC | 20 | Q1 2024 | 5.6% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| iBio, Inc. | April 09, 2024 | 650,000 | 7.6% |
| OCULAR THERAPEUTIX, INC | February 14, 2024 | 6,070,000 | 5.5% |
| SANUWAVE Health, Inc. | February 14, 2024 | 115,493,554 | 9.1% |
| HARROW, INC. | February 09, 2024 | 3,820,000 | 10.9% |
| Jounce Therapeutics, Inc.Sold out | February 09, 2024 | 0 | 0.0% |
| Tracon Pharmaceuticals, Inc. | February 09, 2024 | 10 | 0.0% |
| Context Therapeutics Inc. | January 05, 2024 | 820,000 | 5.1% |
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-09-19 |
| SC 13G/A | 2024-09-18 |
| 3 | 2024-09-12 |
| 4 | 2024-09-12 |
| 4 | 2024-09-12 |
| SC 13G/A | 2024-09-12 |
| 4 | 2024-09-10 |
| N-PX | 2024-09-03 |
| 13F-HR | 2024-08-14 |
| 4 | 2024-07-18 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.